Recently, renewed discussion on the therapeutic potential of GIP in the long-term treatment of type 2 diabetes has been triggered by clinical findings with the dual GIP/GLP-1 receptor agonist tirzepatide [83]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.